Ελληνικά
School of Medicine
University of Patras
>University of Patras
HQA
Personel - GOUMENOS DI.
  1. Home
  3. Personel
  5. Professors

GOUMENOS DIMITRIS, Professor

GOUMENOS DIMITRIS

Sector: Division of Internal Medicine Ι

Clinic/Laboratory: Department of Internal Medicine

Knowledge Subject:

Research Area: Internal Medicine - Nephrology

Patras University Hospital Rion 26504 Patras - Greece Building A - 4th floor

+30 2613 603361 +30 2610 994424 dgoumenos@upatras.gr dgoumenos@med.upatras.gr

Download Curriculum Vitae

Summary of Curriculum Vitae

Professor Dimitrios S. Goumenos was born in Piraeus in 1958 and graduated from Medical School-University of Athens, Greece in 1982. He did his did training in Internal Medicine and Nephrology in Department of Nephrology and Transplantation of Laikon General Hospital of Athens, Greece and got a 2-year fellowship from ‘Alexandros Onasis Foundation’ for further training in Nephrology and Renal Transplantation in Sheffield Kidney Institute, University of Sheffield, Northern General Hospital, UK.  He worked in Sheffield Kidney Institute as Honorary Registrar -Clinical and Research Fellow for 2 years (1992 and 1993) and involved in a clinical project in the therapeutic management of patients with various glomerulonephritides and in a basic research project looking for parameters involved in the development of renal scarring. In 1994, he returned to Greece and attached to the Department of Internal Medicine in the Medical School of the University of Athens and continued to work on the role of growth factors in the renal scarring. In 1997, he was appointed as Assistant Professor of Internal Medicine-Nephrology in the University Hospital of Patras (Medical School of Patras-Greece), promoted in 2005 to Associated Professor and in 2009 to Professor of Internal Medicine – Nephrology and Head of the Department of Nephrology and Renal Transplantation, in the University Hospital of Patras. His research activity is concentrated on the management of patients with glomerulonephritis and on the mechanisms of progression of renal disease. Other topics of his research are obesity related glomerulopathy, the role of transgelin and transglutaminase in the development of renal scarring and the study of newer potentially more specific markers such as proteomics. He has been part of the COST network WG1 (Eurocup) for proteomics in kidney injury and of Immunonephrology Group of ERA-EDTA taking part in VALIGA and post-VALIGA studies in patients with IgA nephropathy. He has kept a very close contact with Sheffield Kidney Institute for more than 20 years with ongoing research collaboration and annual teaching in the Masters in Nephrology Course. Currently he is developing a Biobank at the lab of Department of Nephrology of University of Patras in order to study new biomarkers in patients with earky stages of chronic kidney disease. He has 95 publications in peer reviewed journals, 1300 citations and h-index: 20. He has been ex-President of the Hellenic Society of Nephrology (2014 -2016), President of the Scientific Committee of University Hospital of Patras and currently, he is Head of the School of Medicine of University of Patras from October 2015 and Ordinary Council Member of European Dialysis Association (ERA -EDTA) from June 2017.

Undergraduate Courses

Selected Publications

  1. Zavvos V, Buxton AT, Evans C, Lambie M, Davies SJ, Topley N, Wilkie M, Summers A, Brenchley P, Goumenos DS , Johnson TS. A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. Kidney Int. 2017 Jul 
  2. Djudjaj S, Papasotiriou M, Bülow RD, Wagnerova A, Lindenmeyer MT, Cohen CD, Strnad P, Goumenos DS, Floege J, Boor P Keratins are novel markers of renal epithelial cell injury.Kidney Int. 2016;89(4):792-808.
  3. Serino G, Pesce F, Sallustio F, De Palma G, Cox SN, Curci C, Zaza G, Lai KN, Leung JC, Tang SC, Papagianni A, Stangou M, Goumenos D, Gerolymos M, Takahashi K, Yuzawa Y, Maruyama S, Imai E, Schena FP. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney Int. 2016 ;89(3):683-92.
  4. Kalavrizioti D, Gerolymos M, Rodi M, Kalliakmani P, Provatopoulou S, Eleftheriadis T, Mouzaki A, Goumenos DS. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome? Cytokine 2015;76(2):260-9.
  5. Kakkos SK, Tsolakis IA, Papadoulas SI, Lampropoulos GC, Papachristou EE, Christeas NC, Goumenos D, Lazarides MK. Randomized controlled trial comparing primary and staged basilic vein transposition. Front Surg. 2015;2:14.
  6. Pieri M, Stefanou C, Zaravinos A, Erguler K, Stylianou K, Lapathitis G, Karaiskos C, Savva I, Paraskeva R, Dweep H, Sticht C, Anastasiadou N, Zouvani I, Goumenos D, Felekkis K, Saleem M, Voskarides K, Gretz N, Deltas C. Evidence for activation of the unfolded protein response in collagen IV nephropathies. J Am Soc Nephrol. 2014;25(2):260-75.
  7. Papasotiriou M, Kalliakmani P, Huang L, Gerolymos M, Goumenos DS, Johnson TS. Does treatment with corticosteroids and cyclosporine reduce transglutaminase type 2 expression in the renal tissue of patients with membranous nephropathy? Nephron Clin Pract. 2012;121(1-2):c60-7
  8. Gerolymos M, Karagianni F, Papasotiriou M, Kalliakmani P, Sotsiou F, Charonis A, Goumenos DS. Expression of transgelin in human glomerulonephritis of various etiology. Nephron Clin Pract. 2011;119(1):c74-82.
  9. Kalliakmani P, Koutroulia E, Sotsiou F, Vlachojannis JG, Goumenos DS. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology 2010;15(8):762-7.
  10. Goumenos DS, Kawar B, El Nahas M, Conti S, et al. Early histological changes in the kidney of people with morbid obesity. Nephrol Dial Transplant. 2009;24(12):3732-8.
  11. Goumenos DS, Katopodis KP, Passadakis P, Vardaki E et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol. 2007;27(3):226-31.
  12. Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin Nephrol. 2006;65(5):317-23.
  13. Goumenos DS, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis JG. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol. 2004 61(1):17-24
  14. Goumenos DS, Davlouros P, El Nahas AM, Ahuja M, Shortland JR, Vlachojannis JG, Brown CB. Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Nephron Clin Pract 2003;93(2):C58-68
  15. Goumenos DS, Tsakas S, El Nahas AM, Alexandri S, Oldroyd S, Kalliakmani P, Vlachojannis JG. Transforming growth factor-beta (1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant. 2002 Dec;17(12):2145-52
  16. Goumenos D, Tsomi K, Iatrou C, Oldroyd S, et al. Myofibroblasts and the progression of crescentic glomerulonephritis. Nephrol Dial Transplant. 1998 ;13(7):1652-61
  17. El Nahas AM, Muchaneta-Kubara EC, Zhang G, Adam A, Goumenos D. Phenotypic modulation of renal cells during experimental and clinical renal scarring. Kidney Int Suppl. 1996 May;54: S23-7.
  18. Goumenos DS, Brown CB, Shortland J, El Nahas AM. Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Transplant 1994;9(10):1418-25.

Selected Presentations

  1. Obesity and kidney disease in humans. 4th Congress of Serbian Society of Nephrology, Belgrade 3-6 November 2016.
  2. Proteinuria and human kidney disease progression. i Mode – CKD regular meeting, Skopje 20-22 March 2015.
  3. Glomerulonephritis Workshop. Global Mater Class of Global Kidney Academy, Athens 27-29 October 2014.
  4. Cyclosporine in glomerular disease: What is the indication?ERA-EDTA CME Course: New trends in pathogenesis and treatment of glomerular diseases. Patras, 19-20 May 2011.
  5. Focal Segmental Glomerulosclerosis. 9th BANTAO Congress Antalya, Turkey, November 2009.
  6. Factors implicated in the development of tubulointerstitial injury and progression of human glomerular disease Meeting of the COST Action EuroKUP (Kidney and Urine Proteomics) Mario Negri Institute Bergamo, Italy, 1-2 October 2008.
  7. Meet the expert: Immunossuppressive treatment of glomerulonephritis. Sheffield Kidney Institute, Northern General Hospital, UK, 16th April 2007.
  8. Pathogenesis and mechanisms of progression in human glomerulonephritis –Lecture Sheffield Kidney Institute, Northern General Hospital, UK, 27th April 2006.
  9. The Greek Experience with cyclosporine in nephrotic syndrome: Membranous Glomerulopathy Scientific meeting ‘Extending the Horizon in Immunosuppression’ Paphos, Cyprus, 8-9 March, 2002.
  10. Glomerulonephritides: Classification, Pathogenesis, Mechanisms of injury. Sheffield Kidney Institute, Northern General Hospital, UK 3th December 2002.
  11. Present and future challenges in cardiovascular risk associated with renal anaemia: Epidemiology of various types of left ventricular hypertrophy in patients with chronic renal failure and cardiovascular mortality 5TH Congress of the Balkan Cities Association of Nephrology Dialysis, Transplantation and Artificial Organs (BANTAO). Thessaloniki, Greece Sept.30-Oct.3, 2001
  12. Immunosuppressive regimens in the treatment of glomerulonephritis Sheffield Kidney Institute, Northern General Hospital, UK 12th December 2000.